Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
$0.30
$0.58
$0.18
$16.00
$10.94M0.84822,537 shs309,164 shs
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$1.21
-2.0%
$1.41
$0.72
$6.77
$14.69M0.8981,780 shs30,525 shs
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
$1.43
$0.51
$77.77
$30.72M1.681.37 million shs941,400 shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$2.13
$1.92
$1.71
$20.28
$4.89M4.22163,546 shs6,953 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
0.00%0.00%0.00%0.00%0.00%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
+1.65%-2.77%-20.65%+61.84%-77.64%
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.00%0.00%0.00%0.00%0.00%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
+2.11%+5.71%+4.93%-11.62%-99.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
2.4372 of 5 stars
3.25.00.00.00.01.70.6
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/AN/AN/AN/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
0.00
N/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
2.33
Hold$4.50273.44% Upside
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.00
N/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
$14.07M0.78N/AN/A$1.96 per share0.15
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$43.95M0.33N/AN/A$4.25 per share0.28
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/AN/AN/AN/A$2.74 per shareN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$8.04M0.61N/AN/A($3.66) per share-0.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
-$81.58M-$1.89N/AN/AN/AN/A-107.67%-61.40%N/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
-$97.01MN/A0.00N/AN/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-$8.27MN/A0.00N/AN/AN/AN/AN/A

Latest FREQ, RDHL, HOOK, and ORPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
N/AN/AN/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/AN/AN/AN/AN/A
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
N/A
5.81
5.81
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/A
3.61
3.61
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.14
1.80
N/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/A
0.54
0.37

Institutional Ownership

CompanyInstitutional Ownership
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
13.18%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
63.88%
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
10.74%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
7.20%

Insider Ownership

CompanyInsider Ownership
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
16.80%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
3.30%
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
6.81%
CompanyEmployeesShares OutstandingFree FloatOptionable
Frequency Therapeutics, Inc. stock logo
FREQ
Frequency Therapeutics
4636.52 million30.39 millionNot Optionable
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
16012.19 million11.79 millionOptionable
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
14135.31 millionN/ANot Optionable
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
2102.30 million2.14 millionNo Data

Recent News About These Companies

RedHill Biopharma Ltd. (RDHL) - Yahoo Finance
RedHill Biopharma receives non-compliance letter from Nasdaq
RedHill Biopharma announces publication in journal on Opaganib
RedHill Biopharma to submit UK MAA for Talicia
RedHill to file FDA-approved Talicia for UK marketing

New MarketBeat Followers Over Time

Media Sentiment Over Time

Frequency Therapeutics stock logo

Frequency Therapeutics NASDAQ:FREQ

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

HOOKIPA Pharma stock logo

HOOKIPA Pharma NASDAQ:HOOK

$1.20 -0.03 (-2.03%)
As of 02:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Orphazyme A/S stock logo

Orphazyme A/S NASDAQ:ORPH

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Redhill Biopharma stock logo

Redhill Biopharma NASDAQ:RDHL

$2.13 0.00 (0.00%)
As of 02:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.